Immunohistochemical expression of survivin and Bcl-2 in prostatic adenocarcinoma
New Egyptian Journal of Medicine [The]. 2005; 33 (5 Supp.): 74-83
in En
| IMEMR
| ID: emr-73922
Responsible library:
EMRO
ABSTRACT
The present work was carried out to detect the expression of survivin and Bcl-2 in twenty cases of prostatic adenocarcinoma, and to determine its correlation with the different clinicopathologic parameters including age of the patient, serum prostate -specific antigen [PSA] level, clinical stage and Gleason score. Positive staining for both survivin and Bcl-2 was seen as brown cytoplasmic staining. A semiquantitative method based on both intensity and distribution of staining was used to score immunohistochemical positivity. 75% and 35% of the studied cases of prostatic adenocarcinoma showed positive staining for survivin and Bcl-2 respectively. 20% of cases showed concomitant expression of both survivin and Bcl-2. Expression of survivin alone was detected in 55% of cases, while 15% of cases expressed Bcl-2 only. No correlation was found between survivin and Bcl-2 expression [p=0.176]. A significant association was detected between survivin expression and the Gleason score of prostatic adenocarcinoma, where p=0.004. Another significant correlation was found between Bcl-2 expression and the tumor stage [p=0.007]. Overexpression of survivin and Bcl-2 in prostatic adenocarcinoma indicate their possible role in tumorigenicity and/or tumor progression. A definite correlation was found between survivin expression and the Gleason score of prostatic adenocarcinoma. In addition,a significant correlation was detected between Bcl-2 expression and tumor stage. Survivin and Bcl-2 may serve as targets for apoptosis-based therapy of prostatic adenocarcinoma
Search on Google
Index:
IMEMR
Main subject:
Prostatic Neoplasms
/
Immunohistochemistry
/
Adenocarcinoma
/
Neoplasm Staging
Limits:
Humans
/
Male
Language:
En
Journal:
New Egypt. J. Med.
Year:
2005